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Chemotherapy-induced nausea and vomiting are concerning adverse events resulting from
cancer treatment, and current guidelines recommend the use of neurokinin-1-selective
antagonists, such as fosaprepitant, in highly emetogenic schemes. However, the implemen-
tation of this strategy may be limited by the cost of treatment. GSTP1 c.313A>G genotype
was recently described as a predictor of vomiting related to high-dose cisplatin. We hypothe-
sized that the inclusion of routine GSTP1 c.313A>G screening may be promising in financial
terms, in contrast to the wide-spread use of fosaprepitant.
Methods
A cost-minimization analysis was planned to compare GSTP1 c.313A>G genotyping versus
overall fosaprepitant implementation for patients with head and neck cancer under chemor-
adiation therapy with high-dose cisplatin. A decision analytic tree was designed, and condi-
tional probabilities were calculated under Markov chain Monte Carlo simulations using the
Metropolis-Hastings algorithm. The observed data included patients under treatment with-
out fosaprepitant, while priors were derived from published studies.
Results
To introduce screening with real-time polymerase chain reaction, an initial investment of U$
39,379.97 would be required, with an amortization cost of U$ 7,272.97 per year. The mean
cost of standard therapy with fosaprepitant is U$ 243.24 per patient, and although the initial
cost of routine genotyping is higher, there is a tendency of progressive minimization at a
threshold of 155 patients (Credible interval–CI: 119 to 216), provided more than one sample
is incorporated for simultaneous analysis. A resulting reduction of 35.83% (CI: 30.31 to
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41.74%) in fosaprepitant expenditures is then expected with the implementation of GSTP1
c.313A>G genotyping.
Conclusion
GSTP1 c.313A>G genotyping may reduce the use of preventive support for chemotherapy
induced nausea and lower the overall cost of treatment. Despite the results of this simula-
tion, randomized, interventional studies are required to control for known and unknown con-
founders as well as unexpected expenses.
Introduction
Chemotherapy-induced nausea and vomiting (CINV) are dose-limiting adverse events that are
reported in up to 80% of patients subjected to cancer treatment without additional support. [1]
Severe CINV is linked to hospitalizations as well as quality of life impairment. [2,3] Hence, the
prevention of CINV is of utmost importance in cancer care. Aprepitant and fosaprepitant (apre-
pitant prodrug) are neurokinin-1 (NK1)-selective antagonists and known to effectively reduce
vomiting by blocking substance P brain-stem emetic activity. [4,5] These agents have been
approved for over a decade by the Food and Drug Administration, following positive results
from phase III trials demonstrating a reduction of approximately 20% in the risk of CINV in
known emetogenic schemes. [6,7] Since then, most recommendation guidelines have included
NK1 antagonists in addition to dexamethasone and 5-hydroxytryptamine (5-HT3) receptor
antagonists for the prevention of CINV in highly emetogenic therapies, such as those including
high-dose cisplatin (CDDP), [8] resulting in substantial reductions in CINV occurrence. [8,9]
On the other hand, the financial burden of cancer treatment remains a constant concern
worldwide, [10–12] and the access to fosaprepitant and aprepitant for highly emetogenic chemo-
therapy schemes may be limited, particularly in developing countries, as a consequence of income
restrictions. Possible strategies to address this major health concern could include the adoption of
techniques related to precision medicine to better predict an individual’s response or tolerance to
treatment, thereby selecting patients who would benefit from a certain therapy or support. In this
case, pharmacogenomics could play a potential role in identifying benefit/risk groups. [13]
Recently, patients with head and neck cancer (HNC) under chemoradiation therapy with
high-dose CDDP were prospectively evaluated in our institution, aiming to identify a possible
correlation between single nucleotide polymorphisms (SNPs) involved in CDDP metabolism
and the occurrence of CINV. [14] In this setting, the prophylaxis consisted of dexamethasone
in combination with the 5-HT3 antagonist ondansetron, which is supported by the public
health system in Brazil. Among the SNPs studied, the glutathione S-transferase P gene
(GSTP1) c.313 (NM_000852.3, rs1695) was highlighted. In this prospective cohort, the AG or
GG genotype conferred a 4.28 higher risk of CINV, with 46.7% of patients reporting grade 2 or
greater events in contrast to 18.6% of patients with the AA genotype, thus demonstrating the
potential value of this SNP as a predictor for CINV. Although this study is the first to report
the association between GSTP1 c.313 A>G and CINV secondary to cisplatin, similar results
were suggested in a recent multifactorial risk model evaluation of a distinct chemotherapy
scheme, considered to be highly emetogenic. [15] In the latter, 324 patients with breast cancer
were submitted to FAC (combination of doxorubicin, 5-fluorouracil, and cyclophosphamide),
in which the presence of the variant allele was related to an odds ratio (OR) of 2.20 higher risk
of CINV, with borderline significance (95% Confidence interval 1.00–4.82, p = 0.049)
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The GSTP1 gene encodes the Pi1 protein involved in the inactivation of CDDP through its
conjugation to glutathione, promoting cellular clearance. [16] Therefore, it is possible to
hypothesize that functional polimorphisms of GSTP1 may influence toxicity and treatment
efficacy related to CDDP, as higher and longer intracellular exposure to active metabolites
may occur. The possible relation of GSTP1 c.313 A>G and overall toxicity to chemotherapeu-
tical agents was already described in gastric and breast cancer regimens. [17,18] In a meta-
analysis of 12 studies reporting the incidence of adverse events for patients with breast cancer,
the presence of G allele for GSTP1 c.313 A>G was associated with increased toxicity (OR 1.35,
95% Confidence interval 1.07 to 1.71, p = 0.011), including either hematological, gastrointesti-
nal, neurological or non specified reports. [18] Because the protein encoded by the variant G
confers reduced catalytic activity compared to that with the A allele, [16,19] the association of
the AG or GG genotype with vomiting may be attributed to the accumulation of CDDP in epi-
thelial enteroendocrine cells in the gastrointestinal tract. This results in serotonin secretion
and stimulation of chemoreceptor trigger zones. [20,21]
The implementation of genotyping in daily practice is a developing field that could poten-
tially bring benefit to patients regarding treatment decision making and reduction of overall
costs. [13,22] Several studies have suggested the cost effectiveness of SNP assessments in the
prevention of drug-related adverse events; however, no study related to CINV prediction has
been performed to date. [23] Considering the favorable evidence for CINV screening using
GSTP1 and the costs of treatment, patient selection could be improved with the implementa-
tion of real-time-polymerase chain reaction (real-time PCR) for GSTP1 in clinical practice.
We thus performed this cost-minimization study in order to estimate the possible financial
impact of GSTP1 c.313A>G genotyping for predicting CINV risk assessment and selecting
patients for fosaprepitant prescription.
Materials and methods
Decision analytic model
Chemoradiation with high-dose CDDP is considered the current standard therapy for HNC,
either in neoadjuvant, adjuvant, or locally advanced disease settings. [24,25] The chemother-
apy protocol considered for the study consists of intravenous CDDP at a dose of 100 mg per
square meter of body surface area on days 1, 22, and 43 of radiotherapy, totaling three cycles.
[26] Ideally, taking into account the high emetogenic risk of this regimen, fosaprepitant should
be included as CINV prophylaxis as a premedication for all cycles. [8]
With the hypothesis of including GSTP1 c.313 A>G testing, a decision analytic model (Fig
1) was then applied to analyze the cost and transitional probabilities involved. In this visual
representation, high-risk patients for vomiting (AG or GG) would be prescribed fosaprepitant
in all cycles, while low-risk patients (AA) would receive the combination of dexamethasone
and ondansetron, with the indication of fosaprepitant in subsequent cycles only in the pres-
ence of grade 3 or higher CINV, according to the National Cancer Institute (NCI)—Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03. The no genotyping (stan-
dard) branch represented the current standard of care, not involving genotype selection and
including the recommended prophylaxis with fosaprepitant starting at treatment initiation
(D1). For this conditional model, the following information was crucial:
• P1—the probability of a high-risk CINV genotype (or GSTP1 c.313 A>G AG or GG);
• P2—the probability of grade 3 of higher nausea in patients not using fosaprepitant;
• The probability of continuing treatment in cycle 2 –D22 (P3) and cycle 3 –D43 (P4)
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Cost incorporation
The overall cost of treatment for both conditional settings was calculated following some pre-
liminary suppositions. First, the analysis was based on the premise that the rate and dose of
CDDP prescriptions, as well as those of additional support drugs (dexamethasone and ondanse-
tron), would be similar between the two hypothetical branches (genotyping or standard) and
could therefore be suppressed in the calculation. Furthermore, considering that only the consol-
idated percentage of CINV grades 3 or higher was described in the observed data and previously
published evaluations, a constant rate of toxicity was then assumed for each prescription phase,
with a consequent overestimation of this risk. The direct costs of medical agents, real-time PCR
materials, and manpower are detailed in Table 1. The quotations for the chemotherapy regimen
and support drugs were obtained in local currency (BRL) by consulting the local department of
medical supplies and subsequently converted to US Dollars with the median exchange rate of 1
US$ for 3.70 BRL (Focus-BC report for 17 August 2018, from the Central Bank of Brazil).
For the costs of laboratory analysis, the information was gathered by the Cancer Genetics
Laboratory (Laboratorio de Genética do Cancer—LAGECA) staff from our institution (State
University of Campinas–UNICAMP), in US Dollars. For every real-time PCR procedure, four
controls (one negative and three positive) were added. Potential losses of reagents and material
were also incorporated, considering and addition of 10% from the original cost, for both DNA
extraction and PCR. We carefully evaluated reagents’ durability and expiration dates for the
estimation of quantities. Further details regarding the DNA extraction and real-time PCR
acquisition are summarized in S1 and S2 Tables, respectively. Manpower was calculated under
Fig 1. Decision analytic model. Visual representation of the decision analytic model, with the inclusion of GSTP1 c.313 A>G genotyping for patient selection, prior to
treatment initiation. In the genotyping branch, patients with AG or GG for GSTP1 c.313 A>G (high risk) would receive fosaprepitant as a primary preventive measure.
Patients with low risk (AA) genotype would receive fosaprepitant only in the presence of grades 3 or higher CINV, for subsequent cycles. The standard branch of the
model represents the usual practice, without prior patient genotype assessment, including fosaprepitant since D1. CRT: chemoradiation.
https://doi.org/10.1371/journal.pone.0213929.g001
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the assumption that the GSTP1 c.313 A>G test would not be an exclusive task (S3 Table).
Hence, the time for DNA extraction, real-time PCR, and data collection were calculated, and
the cost of manpower was estimated according to the time consumed for laboratory analysis.
Additionally, aiming to better simulate clinical practice, we performed overall cost calcula-
tions considering either a single test, or simultaneous evaluations. The real-time PCR machine
of choice is capable of performing 96 tests per turn, while it is possible to extract DNA from 12
samples simultaneously. In our service, receiving an average of 300 patients with this treatment
indication per year, we considered seven days (six patients weekly) as the maximum time from
the patient sample collection upon admission to the final result and decision making. We then
performed simulations of up to six samples at once, and evaluated their respective cost
reductions.
The initial investment included the necessary machinery for the real-time PCR GSTP1
c.313 A>G testing (StepOnePlus Real-Time PCR System and Software, Thermo Fisher Scien-
tific Inc.), assuming an annual amortization rate of 20%. [27] The overall value of the equip-
ment was incorporated into the amortization, despite the strong possibility of other unrelated
real-time PCR tests being performed with the same machine. Therefore, it is plausible to
assume that the annual amortization cost would be lower than estimated in this analysis. How-
ever, we decided to preferably overestimate the expenditures taking into account the intangi-
bility of additional procedures and savings.
Statistical analysis
The cost-minimization analysis was performed by comparing the incremental cost for the
inclusion of real-time PCR genotyping to the implementation of the standard CINV prophy-
laxis with fosaprepitant. In accordance with the Bayesian Bernoulli model, the posterior distri-
bution of probabilities is computed from previously published sample sets (priors) and from
binomial likelihood functions that describe the distribution of the selected data. In this case,
the observed data consist of a prospective non-interventional study performed in the same
Table 1. Cost incorporation summary.
Recurrent Costs Overall Cost (US$)
Treatment (price per unit)
Fosaprepitant 150 mg $81.08
Dexamethasone 2,5 mL (4mg/mL) $0.12
Ondansetron 8mg/4ml $0.15
Cisplatin 1mg/ml 50 ml $4.86





Test specific and tax (per month)





Annual amortization cost (20%) $7,272.97
Summary of direct costs from recurrent (medical agents, PCR materials, and manpower) and investment
expenditures in US Dollars.
https://doi.org/10.1371/journal.pone.0213929.t001
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institution, where 88 patients were submitted to high-dose CDDP and radiotherapy without
the use of fosaprepitant. [14] For the prior risk of the GSTP1 c.313 AG or GG genotype, we
considered an additional prospective case-control study from a similar sample population of
229 patients. [28] The probability of grade 3 or 4 CINV was collected from a current meta-
analysis (three-weekly CDDP arm), [29] while the chance of chemotherapy dropouts and sus-
pensions was obtained from the intervention arm (N = 179) of a randomized clinical trial
assessing high-dose CDDP and radiotherapy. [30] Only aggregated or de-identified data were
used for this analysis, thus maintaining the confidentiality of the subjects involved in the
included studies.
Following the probabilistic model assembly, Markov chain Monte Carlo (MCMC) simula-
tions with 12,500 iterations using the Metropolis Hastings algorithm (MHA) were performed,
with a burn-in phase of 2,500. [31] The MHA sampled repeatedly several random values
extracted from the Bayesian Bernoulli model to estimate parameters–such as means, medians,
and credible interval (CI)–for the posterior probabilities. The resulting means were then
applied according to each corresponding hypothetical branch to calculate the total amount of
fosaprepitant doses administered and the final respective costs (S1 Appendix). Trace plots, his-
tograms, efficiency levels, and autocorrelation graphs were analyzed to validate the quality of




The consolidated results from the MCMC simulations for each posterior probability are
detailed in Table 2. The frequency of the GSTP1 c.313 AG or GG genotype (high risk for
CINV) was estimated to be 58.7% (CI from 53.8% to 63.4%), meaning that in the hypothetical
genotyping branch, 41.3% of patients under chemoradiation therapy could be initially allo-
cated to receive treatment without fosaprepitant. Regarding the chance of receiving subse-
quent chemotherapy cycles, 94.7% (CI from 91.7% to 97%) of patients were expected to
continue treatment in D22 and 74.8% (CI from 69.2% to 80%) in D43. The rate of grades 3 or
greater nausea during the entire treatment period for the simulation was 13.9% (CI from 10%
to 18.1%). Consequently, it was calculated that the same percentage of patients would receive
fosaprepitant in the following cycles, if continuing chemotherapy.
All resulting diagnostic trace plots, histograms, efficiency levels, and autocorrelation plots
are included in S2 Appendix.
Table 2. Markov Chain Monte Carlo simulations.
Observed Data (Binomial) Prior
(Beta)
Simulation Results
Probabilities Events Total Events No Events Mean Median Credible Interval
GSTP1 High Risk (P1) 45 88 178 114 0.587 0.586 0.538–0.634
Grade 3/4 Nausea (P2) 4 43 33 191 0.139 0.138 0.100–0.181
Second Cycle Administration (P3) 86 88 160 12 0.947 0.948 0.917–0.970
Third Cycle Administration (P4) 64 86 120 40 0.748 0.748 0.692–0.800
Markov chain Monte Carlo simulations performed by Metropolis-Hastings algorithm, describing binomial, beta distributions, as well as the resulting proportions for
each simulation and their respective credible intervals.
Notes: MCMC iterations = 12,500; Burn-in = 2,500; MCMC sample size = 10,000
https://doi.org/10.1371/journal.pone.0213929.t002
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Sample quantity simulation
With the aim of replicating various scenarios from clinical practice, where patients may be
included for PCR simultaneously, costs were calculated according to sample quantity for one
PCR procedure. The detailed cost descriptions and time consumed for each laboratory stage
are summarized in Table 3. Once more than one sample is included for genotyping, costs
related to materials, manpower and reagents diminish. This decline can be explained by an
optimization of manpower working time, and the use of less material regarding negative and
positive controls.
Following the overall cost calculation, we then estimated the cost reduction for each sce-
nario, as illustrated in Fig 2. It is possible to observe that the procedure of PCR selection
becomes cost-beneficial once a minimum of two samples are incorporated. The maximum sav-
ing is obtained with the possibility of performing real-time PCR in six samples per turn. The
time consumed from the patient inclusion and sample collection until the analysis of results
will be dependable on the institutional rate of patient admissions. In a service with an average
of 300 patients admitted per year, seven days would be the expected duration for the results to
be retrieved.
Recurring and amortization costs
The mean probabilities presented were used to estimate the total amount of fosaprepitant
doses administered for each chemotherapy cycle. This procedure allowed the calculation of the
overall fosaprepitant cost for both branches (Tables A and B in S3 Appendix). For the imple-
mentation of real-time PCR GSTP1 c.313 A>G screening, an initial investment plan of U$
39,379.97 is expected, with an annual amortization cost of U$ 7,272.97. The direct costs per
test, corresponding to manpower and reagents, totaled U$ 39.94 for a two-sample and U$
15.57 for a six-sample analysis.
Cost comparisons
The overall costs are presented in Fig 3. Although the cost of treatment with genotyping is ini-
tially higher than that of the standard branch, we observed a progressive reduction after a
recovery from the annual amortization amount. Considering 300 patients as a proxy for the
maximum number of new cases that can be treated per year in our institution and the perfor-
mance of two samples, the overall cost of GSTP1 c.313A>G testing would be US$ 60,314.65, in
Table 3. Costs per test according to number of samples.
Test Stages Category Sample Quantity per Test
1 2 3 4 5 6
DNA Extraction (3.93 hours) Manpower $38.98 $19.49 $12.99 $9.74 $7.80 $6.50
Reagentsa $1.46 $1.46 $1.46 $1.46 $1.46 $1.46
Real Time PCR
(2.33 hours)
Manpower $23.12 $11.56 $7.71 $5.78 $4.62 $3.85
Materiala $1.07 $0.64 $0.50 $0.43 $0.39 $0.36
Reagentsa $8.56 $5.13 $3.99 $3.42 $3.08 $2.85
Data Reporting
(0.33 hours)
Manpower $3.30 $1.65 $1.10 $0.83 $0.66 $0.55
Total cost per test $76.50 $39.94 $27.76 $21.67 $18.01 $15.57
Detailed costs regarding DNA extraction, real time PCR and data reporting considering samples per test. The time expected for each stage is also described.
a Material and reagents costs were calculated with an addition of 10% expected losses and four controls.
https://doi.org/10.1371/journal.pone.0213929.t003
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contrast to US$ 64,569.75 for the wide-spread prescription of fosaprepitant, resulting in a pro-
jected annual savings of US$ 4,255.10 (Fig 3A). On the other hand, annual savings progress as
the incorporation of samples increases. If six samples are collected and analyzed every week,
the overall cost would correspond to US$ 53,003.72, with a reduction of US$ 11,566.02 annu-
ally (Fig 3B).
The overall costs per patient for both treatment approaches are presented in Fig 4. By evalu-
ating the simulation graph, it is possible to observe an escalating reduction with GSTP1
c.313A>G testing. This finding can be explained by the drop in the amortization cost per test
Fig 2. Cost reduction according to sample quantity. Cost reduction (overall cost from standard approach versus
genotyping selection) calculations taking into account the number of samples per round.
https://doi.org/10.1371/journal.pone.0213929.g002
Fig 3. Overall cost for each hypothetical branch and cost reduction comparison. Overall cost from genotyping and standard approaches, once two (A) and six (B)
samples are included for PCR.
https://doi.org/10.1371/journal.pone.0213929.g003
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as patients are gradually included (see Table C in S3 Appendix, for more details). In the case of
standard therapy, the cost of US$ 243.40 is constant, considering the use of fosaprepitant dur-
ing all chemotherapy cycles.
The mean expense with fosaprepitant use decreases from US$ 243.40 to U$ 156.08 per
patient (CI US$ 141.71 to US$ 169.52) with the real-time PCR test, resulting in a total reduc-
tion of 35.83% (CI 30.31 to 41.74%).
Moreover, the results indicate that given an annual amortization rate of 20%, 155 patients
must be treated per year in order for the genotyping branch to become more advantageous (CI
119 to 216) for a two-sample analysis. Once this threshold is reached, there is a tendency of
progressive cost minimization. An average difference of 9.45% (CI 3.92% to 15.36%) in the
overall cost per patient is then expected with the implementation of GSTP1 genotyping for 300
patients. In the setting of six-sample evaluations, the corresponding threshold is 102 (CI 85 to
126), resulting in an average difference of 19.46% (CI 13.94% to 25.37%).
Discussion
There are more than 686,000 new cases of head and neck carcinomas every year worldwide.
[32] Furthermore, the incidence is predicted to be higher in most developing countries. [33]
The implementation of new technologies as well as supportive agents in cancer therapy has
become a global challenge, [10,12] particularly for countries with low income rates, [11]
despite current recommendations. Within this context, the development and adoption of safe
selection criteria represents a potential strategy to address the financial burden of cancer care.
The GSTP1 polymorphism was described as a promising predictor of CINV in a recent pro-
spective evaluation, in which a subgroup of patients did not report concerning rates of nausea
and vomiting even in the absence of fosaprepitant. [14] The present cost minimization study
was then planned with the aim of more accurately evaluating and comparing the wide-spread
implementation of fosaprepitant versus patient selection based on genotyping. The results of
this simulation suggest a potential benefit in regards to limiting fosaprepitant prescription to
higher CINV risk patients with the GSTP1 AG or GG genotype, in services where the inclusion
of simultaneous samples for PCR is possible without compromising the time for result analysis
and treatment initiation.
Fig 4. Overall cost per patient. Graphical representation of overall cost per patient, considering the complete treatment, in the setting of two-
sample (A) and six-sample (B) analyzes, and their respective credible intervals. The vertical dotted reference line marks the patient threshold
for cost-benefit.
https://doi.org/10.1371/journal.pone.0213929.g004
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There are, nonetheless, limitations to be considered in this study. One of the major
restraints, already much discussed in the literature, relies on the principle that a SNP may not
be the sole determinant of the metabolism of a specific drug; [13,34] other unknown SNPs
could also play a key role in the response and toxicity, representing potential unassessed con-
founders. Consequently, several authors have suggested the use of a shared genetic database
and whole genomic profiling to better characterize pharmacologic predictors. The resulting
requirement for big data analysis has become one of the greatest challenges for current phar-
macogenomics. [22,35] However, we believe that given the high frequency of GSTP1 polymor-
phisms in the studied population, there is sufficient equipoise to support an interventional
study with real-time PCR, in a randomized fashion, that can adjust for known and unknown
confounders in a larger sample set.
There may be additional concerns related to the general applicability of these findings. Var-
iability in drug material costs, toxicity rates, number of samples per test and even SNP fre-
quency may alter the results of this simulation study. Structural heterogeneity, such as the
presence or absence of a laboratorial facility, could further influence cost planning. Further-
more, unaccounted expenditures could play some role in the final cost analysis, although the
price overestimation preferred by the authors for this cost minimization may act as a potential
counterbalance.
In conclusion, GSTP1 c.313A>G genotyping was demonstrated to be a promising predictor
for CINV. This study shows a potential financial advantage to the application of real-time PCR
for the selection of high-risk CINV patients, thereby suggesting the possible implementation
of fosaprepitant for this subgroup. To confirm the assumptions in a cost-effectiveness study,
the benefit of use of GSTP1 genotyping should be demonstrated in a randomized, interven-
tional study. In general, most SNPs remain restricted to observational data, hence limiting the
assessment of detailed cost evaluations and their further implementation in routine practice.
Regarding potential genomic predictors of response or toxicity and in the absence of safety
concerns, more interventional studies on SNP testing can possibly increase the inclusion of
pharmacogenomics in decision making, thus improving precision medicine in the clinic.
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